2022 Nasopharyngeal Carcinoma Gordon Research Conference

摘要 鼻咽癌（Nasopharyngeal carcinoma，NPC）和口咽癌（oropharyngeal carcinoma，OPC）是头颈部两种常见的上皮性恶性肿瘤， 与病毒感染有关的癌症。虽然这两种癌症都起源于咽部，但它们的解剖结构 和地理分布以及病毒连锁是不同的。NPC与EB病毒有关 (EBV)，局限于鼻咽部，在东南亚、北非、格陵兰岛、 还有阿拉斯加在美国（US），它在高加索人中很少见，但在亚洲人中很常见， 西班牙裔和非洲裔美国人。相反，OPC通常与人类乳头瘤病毒有关， (HPV)局限于口咽部，在西半球的白色男性中发病率最高。 这两种独特癌症的病因包括三个重要的辅助因素：宿主遗传学、病毒感染和 环境影响。这些因素如何促进这些癌症的发展是研究 全球众多实验室的焦点。由于它们的位置和早期淋巴扩散的倾向， NPC和OPC都是在晚期诊断的，需要积极的治疗。了解病毒如何 感染促使正常细胞癌变，这些细胞如何逃脱免疫监视，以及 介导肿瘤进展和治疗抗性的关键途径有望产生更好的工具， 早期诊断和有效的治疗，最终将改善这些癌症的结果。 病毒感染、宿主遗传学、宿主免疫功能和流行病学因素的集合，使得 这两种癌症强有力的模型来描绘宿主-病毒-环境相互作用，从而产生新的 对肿瘤发病机制的深入了解。重要的是，同时包含两种不同的病毒驱动的癌症， 小型、亲密的会议将促进合作，并推进这两种癌症的研究步伐。我们 假设2022年的会议，其特点是在NPC的基础，转化和临床研究的前沿 和OPC，为基础科学家、临床医生和工业界提供了一个独特的思想交流论坛， 有助于扩大新知识的翻译到病人护理。我们将通过三个具体的假设来解决这个问题。 目的：（1）通过对鼻咽癌和OPC的研究和临床护理的全面了解， 制定一个令人兴奋的科学计划，并为以下方面的关键互动提供一个激励性的论坛： （2）促进职业发展，提高新的知名度 通过小型会谈和高度参与的海报会议，以及提供部分 会议支持;以及（3）增强NPC GRC参与者的多样性，重点关注女性和URM 与会者和那些来自发展中国家（NPC是地方病），通过我们的努力， 会议支持和促进这些团体的口头介绍。我们相信科学环境 在2022年NPC/OPC GRC会议上创建的新技术将有助于推进病毒驱动头的研究领域， 颈部癌症，以改善这些患者的整体护理和治疗。

Abstract Nasopharyngeal carcinoma (NPC) and oropharyngeal carcinoma (OPC) are 2 common head and neck epithelial cancers that are associated with viral infection. Although both cancers arise from the pharynx, their anatomic and geographic distribution as well as viral linkage are distinct. NPC, which is linked to the Epstein-Barr Virus (EBV), is localized to the nasopharynx and has the highest incidence in Southeast Asia, North Africa, Greenland, and Alaska. In the United States (US), it is rare among Caucasians but is common among ethnic Asians, Hispanics and African Americans. In contrast OPC, which is commonly linked to the Human Papillomavirus (HPV), is localized to the oropharynx and has the highest incidence in white males in the Western hemisphere. The etiologies of these two unique cancers include three significant co-factors: host genetics, viral infection and environmental influences. How these factors contribute to the development of these cancers is the research focus of numerous laboratories worldwide. Because of their locations and proclivity for early lymphatic spread, both NPC and OPC are diagnosed at advanced stage, requiring aggressive therapy. Understanding how viral infection drives normal cells to become cancerous, how these cells escape from immune surveillance, and the critical pathways mediating tumor progression and treatment resistance are expected to lead to better tools for early diagnosis and effective therapies that would ultimately improve outcome of these cancers. The convergence of a virus infection, host genetics, host immune function, and epidemiological factors, makes these two cancers powerful models to delineate the host-virus-environment interactions, thereby yielding new insights into tumor pathogenesis. Importantly, the inclusion of two different virally driven cancers at the same small, intimate meeting will catalyze collaborations and advance the pace of research in both cancers. We hypothesize that the 2022 meeting, which features cutting edge basic, translational, and clinical research in NPC and OPC and provides a unique forum for idea exchange among basic scientists, clinicians, and industry, will help to expand the translation of new knowledge to patient care. We will address this hypothesis via three specific aims: (1) To advance the overall knowledge in research and clinical care of NPC and OPC through the development of an exciting scientific program and provision of a stimulating forum for critical interactions between the basic and clinical scientists; (2) To foster the career development and enhance the visibility of new investigators and trainees through the mini talks and highly engaged poster sessions and provision of partial meeting support; and (3) To enhance the diversity of NPC GRC participants with a focus on woman and URM attendees and those from developing countries (where NPC is endemic) through our effort to provide partial meeting support and promote oral presentations from these groups. We believe that the scientific environment created at the 2022 NPC/OPC GRC meeting will help to advance the field of research in virally-driven head and neck cancers in order to improve the overall care and cure of these patients.